Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity
10.1111/ijpo.12459; PMCID: PMC6309791
© 2018 World Obesity Federation Background: Children with obesity are more likely to suffer gastroesophageal reflux disease, requiring acid-suppression therapy with proton pump inhibitors (PPIs) and no guidelines regarding dosing. Objective: To prospectively evaluate lean-body-weight-based (LBW) dosing of the PPI pantoprazole for children with and without obesity. Methods: Methods: Sixty-two children (6–17 years) received a one-time oral dose of liquid pantoprazole (1.2 mg kg −1 LBW). Plasma pantoprazole concentrations were measured at 10 time points over 8 h and pharmacokinetic (PK) profiles generated using non-compartmental techniques, in order to compare PK parameters of interest between children with and without obesity, while accounting for CYP2C19 genotype. Results: Adjusted for milligram-per-kilogram total body weight (TBW) pantoprazole received, apparent drug clearance (CL/F) was reduced 50% in children with vs. without obesity (p=0.03). LBW-based dosing compensated for this reduction in CL/F (p = 0.15). Conclusion: To achieve comparable systemic PPI exposures for children with and without obesity, we recommend using LBW, rather than TBW-based dosing for pantoprazole.
CYP2C19; drug metabolism; pantoprazole; pediatric obesity
Shakhnovich, V., Abdel-Rahman, S. M., Friesen, C. A., Weigel, J., Pearce, R. E., Gaedigk, A., Leeder, J., Kearns, G. Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity Pediatric Obesity 14, (2019).